These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19622782)

  • 1. Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans.
    Phillips SA; Kung J; Ciaraldi TP; Choe C; Christiansen L; Mudaliar S; Henry RR
    Am J Physiol Endocrinol Metab; 2009 Sep; 297(3):E767-73. PubMed ID: 19622782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
    Kadoglou NP; Kapelouzou A; Tsanikidis H; Vitta I; Liapis CD; Sailer N
    Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):63-8. PubMed ID: 21031343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride.
    Pfützner A; Schöndorf T; Seidel D; Winkler K; Matthaei S; Hamann A; Forst T
    Metabolism; 2006 Jan; 55(1):20-5. PubMed ID: 16324915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.
    Tiikkainen M; Häkkinen AM; Korsheninnikova E; Nyman T; Mäkimattila S; Yki-Järvinen H
    Diabetes; 2004 Aug; 53(8):2169-76. PubMed ID: 15277403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy.
    Phillips SA; Ciaraldi TP; Kong AP; Bandukwala R; Aroda V; Carter L; Baxi S; Mudaliar SR; Henry RR
    Diabetes; 2003 Mar; 52(3):667-74. PubMed ID: 12606507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosiglitazone maleate/metformin hydrochloride: a new formulation therapy for type 2 diabetes.
    Cox SL
    Drugs Today (Barc); 2004 Jul; 40(7):633-43. PubMed ID: 15510236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus.
    Jung HS; Youn BS; Cho YM; Yu KY; Park HJ; Shin CS; Kim SY; Lee HK; Park KS
    Metabolism; 2005 Mar; 54(3):314-20. PubMed ID: 15736108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes.
    Abbasi F; Chang SA; Chu JW; Ciaraldi TP; Lamendola C; McLaughlin T; Reaven GM; Reaven PD
    Am J Physiol Regul Integr Comp Physiol; 2006 Jan; 290(1):R139-44. PubMed ID: 16352858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiazolidinedione addition reduces the serum retinol-binding protein 4 in type 2 diabetic patients treated with metformin and sulfonylurea.
    Lin KD; Chang YH; Wang CL; Yang YH; Hsiao PJ; Li TH; Shin SJ
    Transl Res; 2008 Jun; 151(6):309-14. PubMed ID: 18514142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-sensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle.
    Li W; Tonelli J; Kishore P; Owen R; Goodman E; Scherer PE; Hawkins M
    Am J Physiol Endocrinol Metab; 2007 May; 292(5):E1301-7. PubMed ID: 17213476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes.
    Tonelli J; Li W; Kishore P; Pajvani UB; Kwon E; Weaver C; Scherer PE; Hawkins M
    Diabetes; 2004 Jun; 53(6):1621-9. PubMed ID: 15161771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity.
    Pajvani UB; Hawkins M; Combs TP; Rajala MW; Doebber T; Berger JP; Wagner JA; Wu M; Knopps A; Xiang AH; Utzschneider KM; Kahn SE; Olefsky JM; Buchanan TA; Scherer PE
    J Biol Chem; 2004 Mar; 279(13):12152-62. PubMed ID: 14699128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of metformin and rosiglitazone on peripheral insulin resistance and β-cell function in obesity: a double-blind, randomized, controlled study.
    Li X; Zhang N; Li Y; Shi Y; Li D; Xie Y; Xie Y; Ming J
    J Int Med Res; 2011; 39(2):358-65. PubMed ID: 21672339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous abdominal adipose tissue subcompartments: potential role in rosiglitazone effects.
    Walker GE; Marzullo P; Verti B; Guzzaloni G; Maestrini S; Zurleni F; Liuzzi A; Di Blasio AM
    Obesity (Silver Spring); 2008 Sep; 16(9):1983-91. PubMed ID: 19186324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis.
    Vanderpoel DR; Hussein MA; Watson-Heidari T; Perry A
    Clin Ther; 2004 Dec; 26(12):2066-75. PubMed ID: 15823770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics.
    Ghanim H; Dhindsa S; Aljada A; Chaudhuri A; Viswanathan P; Dandona P
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3553-8. PubMed ID: 16804037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in adiponectin receptor expression in muscle and adipose tissue of type 2 diabetic patients during rosiglitazone therapy.
    Tan GD; Debard C; Funahashi T; Humphreys SM; Matsuzawa Y; Frayn KN; Karpe F; Vidal H
    Diabetologia; 2005 Aug; 48(8):1585-9. PubMed ID: 15991021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of the high-molecular-mass isoform of adiponectin in improved insulin sensitivity with rosiglitazone treatment in HIV disease.
    Qurashi S; Mynarcik DC; McNurlan MA; Ahn H; Ferris R; Gelato MC
    Clin Sci (Lond); 2008 Sep; 115(6):197-202. PubMed ID: 18254722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production.
    Hoo RL; Chow WS; Yau MH; Xu A; Tso AW; Tse HF; Fong CH; Tam S; Chan L; Lam KS
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2777-82. PubMed ID: 17932317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.